FDA Grants Fast-Track Designation to Tazemetostat for DLBCL

The U.S. Food and Drug Administration granted fast-track designation to tazemetostat for patients with relapsed/refractory diffuse large B-cell lymphoma with EZH2-activating mutations. Tazemetostat is an orally administered, first-in-class, small molecule EZH2 inhibitor. The drug is also under investigation in a phase II study for adult patients with solid tumor cancers marked by a genetic loss of INI1.

Source: Epizyme press release, November 28, 2016.

SHARE